Filing Details

Accession Number:
0001209191-16-148156
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-03 16:11:09
Reporting Period:
2016-11-02
Filing Date:
2016-11-03
Accepted Time:
2016-11-03 16:11:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1123494 Harvard Bioscience Inc HBIO Laboratory Analytical Instruments (3826) 043306140
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1504983 E. Robert Gagnon C/o Harvard Bioscience, Inc.
84 October Hill Road
Holliston MA 01746
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-11-02 5,000 $2.33 247,549 No 4 P Direct
Common Stock Acquisiton 2016-11-03 20,000 $2.34 267,549 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. This transaction was executed in two trades at $2.3415 and $2.3258. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Includes (a) a deferred stock award of 88,652 restricted stock units which shall vest in full on May 6, 2018; (b) a deferred stock award of 88,652 restricted stock units which shall vest in four equal installments on January 1, 2017, 2018, 2019 and 2020; (c) a deferred stock award of 19,875 restricted stock units which shall vest in three equal installments on January 1, 2017, 2018 and 2019; (d) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 22,253 shares of common stock held by the Reporting Person.
  3. This transaction was executed in several trades between $2.30 and $2.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Includes (a) a deferred stock award of 88,652 restricted stock units which shall vest in full on May 6, 2018; (b) a deferred stock award of 88,652 restricted stock units which shall vest in four equal installments on January 1, 2017, 2018, 2019 and 2020; (c) a deferred stock award of 19,875 restricted stock units which shall vest in three equal installments on January 1, 2017, 2018 and 2019; (d) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 42,253 shares of common stock held by the Reporting Person.